Status:
WITHDRAWN
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Primary and Secondary Pulmonary Hypertension
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
Detailed Description
Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital. Each patient will undergo Swan-Ganz catheterization an...
Eligibility Criteria
Inclusion
- Patients with primary and secondary pulmonary arterial hypertension
- \-
Exclusion
- Unstable patients or patients with allergy to sildenafil
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00155714
Start Date
November 1 2002
End Date
May 1 2005
Last Update
March 16 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ping-Hung Kuo
Taipei, Taiwan, 100